Genentech eyes lupus market for Gazyva with positive Phase III data readout
Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company…
Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company…
Sanofi's participation at the JP Morgan 43rd Annual Healthcare Conference on 14 January 2025 was marked by a comprehensive overview…
Nuvig Therapeutics has closed a $161m Series B financing round to advance its preclinical pipeline and support NVG-2089’s clinical proof-of-concept…
Kezar Life Sciences has been handed a second clinical hold by the US Food and Drug Administration (FDA) in as…
RAPT Therapeutics has called it quits on a clinical programme evaluating zelnecirnon (RPT193) in inflammatory disorders following feedback with the…
Give your business an edge with our leading industry insights.
AstraZeneca and Amgen have released topline data from a Phase III trial of its inflammatory therapy, Tezspire (tezepelumab) in patients…
Sepsis is a life-threatening complication arising from an infection, which occurs when the body’s response to the infection damages its…
Priovant Therapeutics has high expectations for its lead candidate brepocitinib and plans to evaluate the therapy in multiple autoimmune indications.…
Gilead has presented updated data for its twice-yearly pre-exposure prophylaxis (PrEP) lenacapavir, which has shown nearly perfect efficacy in two…
Resolution Therapeutics has raised £63.5m ($83.3m) in a Series B financing round to develop its macrophage cell therapies. The UK-based…